| US 7,482,013 B2 | ||
| Albumin fusion proteins | ||
| David J. Ballance, Berwyn, Pa. (US); Darrell Sleep, West Bridgford (United Kingdom); Christopher P. Prior, Rosemont, Pa. (US); Homayoun Sadeghi, Doylestown, Pa. (US); and Andrew J. Turner, King of Prussia, Pa. (US) | ||
| Assigned to Human Genome Sciences, Inc., Rockville, Md. (US); and Delta Biotechnology Limited, Nottingham (United Kingdom) | ||
| Filed on Mar. 14, 2005, as Appl. No. 11/78,914. | ||
| Application 11/078914 is a continuation of application No. 09/832501, filed on Apr. 12, 2001, abandoned. | ||
| Claims priority of provisional application 60/256931, filed on Dec. 21, 2000. | ||
| Claims priority of provisional application 60/199384, filed on Apr. 25, 2000. | ||
| Claims priority of provisional application 60/229358, filed on Apr. 12, 2000. | ||
| Prior Publication US 2005/0266533 A1, Dec. 01, 2005 | ||
| Int. Cl. A61K 39/00 (2006.01) | ||
| U.S. Cl. 424—192.1 [435/7.1; 435/69.7; 530/350] | 21 Claims |
| 1. An albumin fusion protein comprising a serum cholinesterase polypeptide fused to an albumin polypeptide, wherein said serum
cholinesterase polypeptide is selected from:
(a) a full-length serum cholinesterase;
(b) a mature serum cholinesterase; and
(c) a fragment of serum cholinesterase, wherein said fragment has serum cholinesterase activity; and wherein said albumin polypeptide is selected from:
(i) a full-length albumin;
(ii) a mature albumin;
(iii) a fragment of albumin, wherein said fragment of albumin has the ability to prolong the serum half-life of the fused
serum cholinesterase polypeptide compared to the unfused serum cholinesterase polypeptide;
(iv) a polypeptide consisting of an amino acid sequence at least 95% identical to SEQ ID NO:18, wherein said polypeptide has
the ability to prolong the serum half-life of the fused serum cholinesterase polypeptide compared to the unfused serum cholinesterase
polypeptide;
(v) amino acids 1 to 585 of SEQ ID NO:18; and
(vi) amino acids 1 to 387 of SEQ ID NO:18.
|